[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Skyline Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100542725","a-long-term-follow-up-study-to-evaluate-skg0106-in-the-treatment-of-patients-with-namd-100542725",false,"NCT06346600","A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD","A Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD)","Inclusion Criteria:\n\nSubjects who only meet all of the following criteria are eligible for this study:\n\n* nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection;\n* Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to complete the study\n\nExclusion Criteria:\n\n* Subjects who are judged by the investigator unsuitable for this study","ALL","50 Years",{"count":19,"type":20},83,"ESTIMATED","OBSERVATIONAL","This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.",[24],"Neovascular (Wet) Age-related Macular Degeneration",[26,27],"nAMD","wAMD","RECRUITING","2024-04-03",{"date":31,"type":32},"2024-04-04","ACTUAL",{"date":34,"type":32},"2024-04-02",{"date":36,"type":20},"2031-03",{"name":38,"class":39},"Skyline Therapeutics","INDUSTRY",10,""]